



# LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY DCKET NO. <b>01994-0024</b>	SERIAL NO. <b>08/966,940</b>	FILING DATE <b>November 10, 1997</b>
APPLICANT <b>Lawrence Tamarkin et al.</b>		GROUP <b>1646</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PM	DA	4,197,237	4/8/80	Leute et al.	260	112	
	DB	4,197,286	4/8/90	Rao	424	1	
	DC	4,213,964	7/22/80	Buckler	424	85	
	DD	4,215,036	7/29/80	Malley	260	112	
	DE	4,218,436	8/19/80	Fitzpatrick	424	85	
	DF	4,329,281	5/11/82	Christenson et al.	260	112	
	DG	4,332,787	6/1/82	Homcy et al.	424	1	
	DH	4,346,074	8/24/82	Gilmour et al.	424	92	
	DI	4,487,780	12/11/84	Scheinberg	424	294	
	DJ	4,578,270	3/25/86	Csizer et al.	424	92	
	DK	4,608,252	8/26/86	Khanna et al.	424	85	
✓	DL	4,639,336	1/27/87	Jouquey et al.	260	397	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO
	DM						
	DN						
	DO						
	DP						

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PM	DR	✓	Kirchner et al., "The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2", <i>Cancer</i> , No. 7, Vol. 67, pages 1862-1864 (1991).
PM	DS	✓	Tomii et al., "Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Carrier", <i>Jpn. J. Med. Sci. Biol.</i> Vol. 44, pages 75-80 (1991).

EXAMINER <b>Prema Merv</b>	DATE CONSIDERED <b>1/28/99</b>
-------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

DOCKET NO.

SERIAL NO.

FILING DATE

01/20/98  
01/24/0024

08/966,940

November 10, 1997

APPLICANT

GROUP

Lawrence Tamarkin et al.

1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PM	AA	4,740,589	04/26/88	Moreno	530	395	
	AB	3,145,144	08/18/64	Ando	167	78	
	AC	3,269,912	08/30/66	Grase	167	78	
	AD	3,577,523	05/04/71	Stolar et al.	424	88	
	AE	4,069,313	01/17/78	Woodhour et al.	424	89	
	AF	3,983,228	09/28/76	Woodhour et al.	424	89	
	AG	3,531,565	09/29/70	Webb et al.	424	92	
	AH	3,149,036	09/15/64	Woodhour et al.	167	78	
	AI	3,399,263	08/27/68	Strazdins et al.	424	88	
	AJ	4,657,763	04/14/87	Finkelstein	424	131	
↓	AK	4,330,530	05/18/82	Baker	424	131	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
PM	AL	WO 91 02078	2/21/91	PCT		
	AM	0 156 242 ✓	12/3/85	Europe		
	AN	0 269 408 ✓	24/11/87	Europe		
Dec 1985	AO	2 334 366 ✓	7/19767	France		

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PM	AP	Fraker, et al., "Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity," <i>The Journal of Experimental Medicine</i> , Vol. 170, pages 1015-1020 (1989) ✓
	AR	Lanzavecchia, "Identifying Strategies for Immune Intervention," <i>Science</i> , Vol. 260, pages 937-944 (1993)
	AS	Paciotti, et al., "Interleukin 2 differentially effects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line <i>in vitro</i> and <i>in vivo</i> ," <i>Anti-Cancer Research</i> , Vol. 8, pages 1233-1240 (1988)
↓	AT	Paciotti, et al., "Interleukin 1 differentially synchronizes estrogen dependent and estrogen-independent human breast cells in G0/G1 phase of the cell cycle," <i>Anti-Cancer Research</i> , vol. 11, pages 25-32 (1991)

EXAMINER

Prema Nent

DATE CONSIDERED

1/28/99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

JCS44 U  
01/20/98  
0024

SERIAL NO.

08/966,940

FILING DATE

November 10, 1997

APPLICANT

GROUP

Lawrence Tamarkin et al.

1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PM	BA	4,339,437	07/13/82	Rosenberg et al.	424	131	
	BB	4,177,263	12/04/79	Rosenberg et al.	424	131	
	BC	4,053,587	10/11/77	Davidson et al.	424	131	
	BD	4,977,286	12/11/90	Nicolaou et al.	552	4	
	BE	5,017,687	05/21/91	Vahlne et al.	530	324	
Revs	BF	4,812,556	04/14/89	Vahlne et al.	530	324	
	BG	4,880,750	11/14/89	Francoeur	436	501	
	BH	5,035,995	07/30/91	Taguchi et al.	435	4	
	BI	4,882,423	11/21/89	Taguchi et al.	530	380	
	BJ	4,906,564	03/06/90	Lyon et al.	435	7	
✓	BK	5,019,497	05/28/91	Olsson	435	7.23	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
PM	BL	2 533 827 ✓	30/9/82	France		
PM	BM	981,242 ✓	1/20/65	England		
	BN					
	BO					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PM	BP	✓	Paciotti, et al., "Interleukin 1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro," <i>Mol. Endocrinol.</i> , Vol. 2, pages 459-464 (1988)
	BR	✓	Coulombe et al., "Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chlorophosphate-induced Phospholipidosis," <i>Journal of Histochemistry and Cytochemistry</i> , Vol. 37, No. 2, pages 139-147 (1989)
	BS	✓	Hashimoto et al., "Action Site of Circulating Interleukin-1 on the Rabbit Brain," <i>Brain Research</i> , Vol. 540, pages 217-223 (1991)
✓	BT		Ohmann et al., "Expresion of Tumor Necrosis Factor- $\alpha$ Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects," <i>Lymphokine Research</i> , Vol. 9, No. 1, pages 43-58 (1990)

EXAMINER

Prema Murty

DATE CONSIDERED

1/26/99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.